March 20, 2018 / 5:57 AM / a year ago

Roche says Tecentriq, chemo cut risk of death in type of lung cancer

ZURICH, March 20 (Reuters) - Roche said on Tuesday a late-stage study showed the Swiss drugmaker's immunotherapy Tecentriq plus chemotherapy cut the risk of disease worsening or death in first-line treatment of people with a type of advanced lung cancer.

"Squamous non-small cell lung cancer is difficult to treat and there have been limited new treatment options over the last few decades," said Sandra Horning, Roche's chief medical officer, adding the company was still awaiting overall survival data in its Impower131 study. (Reporting by John Miller; Editing by Michael Shields)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below